School gastroenteritis is no laughing matter. It means major disruptions on children, families and teachers. A new large scale study of preschool children in Japan compared kids that were fed yoghurt containing lactoferrin to a control group that wasn’t. The study saw a 49% reduction in absent days from school from gastroenteritis.
This is welcome news for consumers and manufacturers. Lactoferrin’s health properties are increasingly being recognised in a positive prevention role, and in broader age groups. This gives supplement manufacturers new possibilities for product innovation and support for realising new market opportunities.
The Preventive effect of Lactoferrin-Containing Yogurt on Gastroenteritis in Nursery School Children.
A randomised prospective study by Tsukahara et al. in 2020 evaluated the efficacy of bLf on gastroenteritis in preschool aged children during the winter season. Pre-school children aged 3-6 years were enrolled in the study and randomised into two groups. 1162 children completed the study. The 578 children in the treatment group were provided 100mg of bLf in yogurt once a day, while the 584 children in the control group received a fruit jelly.
Those children consuming 100mg bLf a day, for at least 3 days a week over a 15 week period demonstrated a significantly lower rate of absent days from school due to vomiting. The study highlights the consumption of 100mg of lactoferrin in yogurt for more than 3 days/week might help alleviate the symptom of vomiting in preschool aged school children during the winter.
New Inferrin™ assists in delivering the benefits of lactoferrin
Bega Bionutrients is launching Inferrinâ„¢, a novel form of microencapsulated lactoferrin. The microencapsulation can help deliver the benefits of lactoferrin by protecting it from degradation in conditions found in the stomach. Inferrinâ„¢ opens up new benefits and applications for lactoferrin based products including foods and dietary supplements.
An initial pilot clinical trial on Inferrinâ„¢ has shown promising results. In a double-blind, randomised, controlled, cross-over trial in healthy males, InferrinTM demonstrated effects on immune markers and the gut microbiome. The study also showed higher levels of lactoferrin in the faecal matter in those consuming InferrinTM. This suggests InferrinTM is indeed surviving degradation in the stomach and influencing the gut microbiome. â€œWe are very excited by these results, and we are already planning to commence a larger scale clinical study later this year to follow up on these results.â€ said Dr Bradley Coleman, Business Manager of Bega Bionutrients.
â€œLactoferrin has been extensively studied and documented for its multiple health benefits in adults and infants. But as a protein, lactoferrin is at risk of being broken down in the mature stomach before it can reach the small intestine, where it is believed much of its activity takes place.â€ said Dr Coleman. â€œUnderstanding this issue, we worked with Australian encapsulation company Progel Pty Ltd and the University of Queensland to develop a form of lactoferrin that is protected through the stomach and released intact in the small intestine. Using Progelâ€™s novel and patented microencapsulation technology, we developed InferrinTM – lactoferrin microencapsulated in common food grade materials. InferrinTM will open new market opportunities for our customers and supports innovative product applicationsâ€.
InferrinTM is ideal for use in foods and dietary supplements. The unique microencapsulation technology allows InferrinTM to use in a wide variety of delivery formats including gels, powders and liquids, as well as the more traditional tablets and capsules.
â€œThe installation of the microencapsulation technology at Begaâ€™s Tatura Milk Industries facility in Victoria, Australia strengthens Begaâ€™s product development and production capabilities in specialty ingredients and life-stage nutritionals.â€
Bega Bionutrients will feature InferrinTM at Vitafoods on in Geneva this May.
Bega Bionutrients Lactoferrin, produced by Tatura Milk Industries Ltd, a wholly owned subsidiary of Bega Cheese Ltd, has been recently granted novel food status in Europe and is available for sale.
The decision of the authority assessing the application states: â€˜â€¦that the bovine lactoferrin produced by Tatura Milk Industries of Australia is substantially equivalent to bovine lactoferrin already authorised for the EU market with respect to composition, nutritional value, metabolism, intended use and level of undesirable substances.â€™
Matthieu Arguillere, General Manager Bionutrients added; â€˜Our lactoferrin is directly extracted from very fresh, premium quality Australian cowâ€™s milk using gentle methods that preserve the integrity and bioactivity of the protein. Our milk comes from some of the best dairying regions in Australia. Thanks to this high quality production, we have built up a substantial lactoferrin business over the past decade supplying customers throughout Asia and Oceania. This approval opens up a number of exciting new business opportunities in Europe and gives European customers a new source of well-established, high quality lactoferrin for their products.â€™
Lactoferrin is used in a number of food products, including infant nutrition, supplements and lifestyle nutrition products.
Bega Bionutrients is a manufacturer and supplier of specialty health and nutrition ingredients. Our aim is to improve the health and wellness of people through delivering innovative bionutrient products. Bega Bionutrients is a division of Bega Cheese Limited, one of Australiaâ€™s largest dairy companies, listed on the Australian Securities Exchange.
Welcome to the Research Highlights area of Bega Bionutrients website
Before you explore the research, we want to inform you that this website contains materials and information intended for general interest only. The information is not a detailed analytical overview, nor medical advice. Many of the research areas highlighted are at an early research stage and the final results may differ.
If you have specific health questions, please consult a medical professional.
By clicking 'I agree' below, you acknowledge that you are using this information for general interest only.